Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
CONCLUSION: SVR12 rates for black/AA (50.8%) and Latino (58.9%) cohorts treated with daclatasvir plus pegIFN alfa-2a/RBV and the lower bound of the 95% Cls were higher than the estimated historical control (black/AA, 26% SVR; Latino, 36% SVR) treated with pegIFN alfa-2a/RBV. These data support daclatasvir use in all-oral direct-acting antiviral combinations. PMID: 31208655 [PubMed] (Source: Annals of Hepatology)
Source: Annals of Hepatology - June 20, 2019 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
Hepatitis B e antigen (HBeAg) seroconversion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections. (Source: Virology Journal)
Source: Virology Journal - May 7, 2019 Category: Virology Authors: Wen Jia, Men Qi Zhu, Xun Qi, Ting Wang, Xiao Wen, Pei Dong Chen, Qing Qi Fan, Wen-Hong Zhang and Ji Ming Zhang Tags: Research Source Type: research
The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy.
Authors: Ma Y, Bao X, Xiong F, Wang J, Gu N, Guo J, Wu H, Lv J Abstract Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) was positively correlated with serological hepatitis B surface antigen (HBsAg) levels in hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients. We evaluated whether Thymopentin (TP5) and interferon (IFN-a) had a synergic effect on HBV cccDNA and the effect of TP5 addition therapy on HBsAg clearance in CHB patients. Real-time PCR experiments were performed to test cccDNA in HepG2.2.15 cells. 45 HBeAg-positive CHB patients had been distributed into two groups rand...
Source: Cellular and Molecular Biology - March 13, 2019 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys(R)
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (MPN) associated with morbidity and mortality resulting from thrombosis or transformation to myelofibrosis and/or secondary acute leukemia. The acquired somatic mutation JAK2V617Fhas been observed in 98% of PV patients, and around 50% of ET patients. Interferon is known to be an effective treatment for chronic MPNs, but unlike hydroxyurea (HU, Hydrea®), it has been shown to target the malignant clone by decreasing JAK2V617Fallelic burden, and in some patients restoring polyclonal hematopoiesis. (Liu et al, Blood. 2003;101...
Source: Blood - November 21, 2018 Category: Hematology Authors: Gilreath, J. A., Tashi, T., Kim, S. J., Hickman, K., Prchal, J. T. Tags: 634. Myeloproliferative Syndromes: Clinical Source Type: research
Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis
In conclusion, the data demonstrate that Ropeginterferon-alfa-2b is able not only to induce hematologic responses but also to improve constitutional symptoms and overall quality of life in prefibrotic PMF. Thus ropeginterferon-alfa-2b warrant further investigation as a treatment option in prefibrotic PMF, where only very limited alternatives exist.DisclosuresGisslinger: Shire: Consultancy, Honoraria; Janssen Cilag: Consultancy, Honoraria; Novartis: Honoraria, Research Funding; AOP Orphan Pharmaceuticals AG: Consultancy, Honoraria, Research Funding. Krejcy: AOP Orphan Pharmaceuticals: Employment. Widmann: AOP Orphan Pharmac...
Source: Blood - November 21, 2018 Category: Hematology Authors: Gisslinger, H., Gisslinger, B., Schalling, M., Krejcy, K., Widmann, R. S., Kralovics, R., Krauth, M.-T. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster II Source Type: research
Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial
ConclusionAfter 36 months of therapy CHR was non-significantly higher in PV patients treated with r-IFNα compared to HU by ITT, irrespective of age. Also, maintenance of CHR was longer for r-IFNα. However, ORR was non-significantly higher for HU. PMR was almost similar between the three groups but the median JAK2V617F reduction was greater for r-IFNα. Toxicity related discontinuation from study therapy was higher for r-IFNα compared to HU.DisclosuresStentoft: Bristol-Myers Squibb: Research Funding; Merck Sharp&Dohme: Research Funding. Hasselbalch: Novartis: Research Funding. (Source: Blood)
Source: Blood - November 21, 2018 Category: Hematology Authors: Knudsen, T. A., Hansen, D. L., Ocias, L. F., Bjerrum, O. W., Brabrand, M., El Fassi, D., Frederiksen, M., Kjaer, L., Kristensen, T. K., Kruse, T. A., Mourits-Andersen, T., Moller, P., Overgaard, U. M., Severinsen, M. T., Skov, V., Stentoft, J., Starklint, Tags: 634. Myeloproliferative Syndromes: Clinical: Interferon Therapy and Mutational Analysis in the MPNs Source Type: research
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
ConclusionPre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.Clinical trial IDNCT: 00922207. (Source: Journal of the Formosan Medical Association)
Source: Journal of the Formosan Medical Association - July 10, 2018 Category: General Medicine Source Type: research
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
Conclusion Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB. Clinical trial ID NCT: 00922207. (Source: Journal of the Formosan Medical Association)
Source: Journal of the Formosan Medical Association - February 16, 2018 Category: General Medicine Source Type: research
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
CONCLUSION: Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB. CLINICAL TRIAL ID: NCT: 00922207. PMID: 29456079 [PubMed - as supplied by publisher] (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - February 15, 2018 Category: General Medicine Authors: Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF Tags: J Formos Med Assoc Source Type: research
Technetium-99m-dimercaptosuccinic acid renal scintigraphy can guide clinical management in congenital hydronephrosis.
Authors: Bazić-Đorović B, Radulović M, Šišić M, Jauković L, Dugonjić S, Pucar D, Janković Z, Beatović S, Janković M, Krstić Z, Ajdinović B Abstract OBJECTIVE: The purpose of this study was to evaluate damage of the kidney with technetium-99m-dimercaptosuccinic acid (99mTc-DMSA) scintigraphy in children with congenital hydronephrosis (CH) and the influence of other postnatal associated diagnoses on abnormal 99mTc-DMSA findings. SUBJECTS AND METHODS: 99mTc-DMSA scintigraphy in 54 children (17 girls and 37 boys), aged from 2 months to 5 years (median 11 months) with 66 congenital hydronep...
Source: Hellenic Journal of Nuclear Medicine - January 14, 2018 Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
Phase III PETALs Interim Analysis: Nilotinib ± PegIFN alfa-2a in Patients With Newly Diagnosed Ph-Positive CP CML
Slideset - Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 19, 2017 Category: Hematology Source Type: research
Immunogenicity of branched polyethylene glycol modified interferon alpha.
Authors: Zhou W, Lu D, Liao X, Zhuang L, Sun L Abstract AIM: To assess the immunogenicity of Peginterferon alpha-2 b(Pegberon) and its effect on the efficacy and safety in phase III clinical trial, by comparing it with the control drug Pegasys. METHODS: 770 patients were recruited in total. 509 were treated with Pegberon plus ribavirin and 261 were treated with Pegasys plus ribavirin. After treatment of 12 and 24 weeks, plasma samples were collected from individual patients for detecting the anti-therapeutic antibodies (ATA) and hepatitis C RNA(HCV RNA), to evaluate the production of antibodies an...
Source: Immunopharmacology and Immunotoxicology - November 7, 2017 Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection
In this study, we aim to identify patient characteristics that predict severe thrombocytopenia induced by peginterferon alfa-2a in hepatitis C virus–infected patients. Demographic, clinical, and genetic data collected from patients with chronic hepatitis C virus infection (n = 232; age ≥18 years) who received peginterferon alfa-2a following eltrombopag treatment. Predictors of severe thrombocytopenia (platelet count below 50 GI/L) were identified using a 2-step approach: First, univariate analysis, using χ2 test for categorical variables and t test for continuous variables, was performed to identify possible p...
Source: American Journal of Therapeutics - November 1, 2017 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research
Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals
Conclusion In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HCV patients. (Source: Hepatobiliary and Pancreatic Diseases International)
Source: Hepatobiliary and Pancreatic Diseases International - October 7, 2017 Category: Gastroenterology Source Type: research
Directly observed therapy of sofosbuvir/ribavirin +/ − peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C‐DOT)
Summary We assessed the feasibility of field‐based directly observed therapy (DOT) with minimal monitoring to deliver HCV treatment to people with a history of drug use in Chennai, India. Fifty participants were randomized 1:1 to sofosbuvir+peginterferon alfa 2a+ribavirin (SOF+PR) for 12 weeks (Arm 1) vs sofosbuvir+ribavirin (SOF+R) for 24 weeks (Arm 2). SOF+R was delivered daily at participant chosen venues and weekly peginterferon injections at the study clinic. HCV RNA testing was performed to confirm active HCV infection and sustained virologic response 12 weeks after treatment completion (SVR12). No b...
Source: Journal of Viral Hepatitis - August 14, 2017 Category: Infectious Diseases Authors: S. S. Solomon, M. S. Sulkowski, P. Amrose, A. K. Srikrishnan, A. M. McFall, B. Ramasamy, M. S. Kumar, S. Anand, D. L. Thomas, S. H. Mehta Tags: ORIGINAL ARTICLE Source Type: research
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients
This study suggests symptomatic response and tumor control effect with interferon-alpha in progressive MPPGLs. (Source: Hormones and Cancer)
Source: Hormones and Cancer - July 26, 2017 Category: Cancer & Oncology Source Type: research
Directly Observed Therapy of Sofosbuvir/Ribavirin +/ ‐ Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C‐DOT)
ConclusionsField‐based DOT of HCV therapy without real‐time HCV RNA monitoring was feasible; however achieving 100% adherence was challenging. SOF+PR appeared superior to SOF+R in achieving SVR12, even when doses were missed with no discontinuations due to side effects. Further exploration of short duration treatment with peginterferon plus direct acting antivirals is warranted.This article is protected by copyright. All rights reserved. (Source: Journal of Viral Hepatitis)
Source: Journal of Viral Hepatitis - July 1, 2017 Category: Infectious Diseases Authors: Sunil S Solomon, Mark S Sulkowski, Pradeep Amrose, Aylur K Srikrishnan, Allison M McFall, Balakrishnan Ramasamy, Muniratnam S Kumar, Santhanam Anand, David L Thomas, Shruti H Mehta Tags: Original Paper Source Type: research
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study
ConclusionBoth dual and triple therapy regimes resulted in SVR rates of >95% in CHC genotype 3 who were naive non-cirrhotics. However, the SVR rates were low in treatment-experienced cirrhotics. (Source: Hepatology International)
Source: Hepatology International - March 31, 2017 Category: Infectious Diseases Source Type: research
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
AbstractBackgroundDaclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.MethodsAI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (
Source: Hepatology International - February 16, 2017 Category: Infectious Diseases Source Type: research
Tolerability and efficacy of pegylated consensus interferon- α in the treatment of chronic hepatitis C.
This study aimed to explore and evaluate the tolerability and antiviral activity of pegylated recombinant human consensus interferon-α (PEG-CIFN) in adults with hepatitis C virus (HCV) infection. A total of 48 adult subjects chronically infected with HCV were divided into five groups, which were treated separately with PEG-CIFN 1.0 µg/kg (n=10), 1.5 µg/kg (n=10), 2.0 µg/kg (n=9) or 3.0 µg/kg (n=10), or pegylated IFN α-2a (Pegasys) 180 µg (n=9) as controls. Symptoms were observed and laboratory results collected to monitor adverse reactions, adjust drug dosage and evaluate tolerabil...
Source: Experimental and Therapeutic Medicine - January 27, 2017 Category: Journals (General) Tags: Exp Ther Med Source Type: research
Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
Conclusion A range of agents (small-molecules, natural products, macrocycles, and non-small molecules) have been described as having the ability to suppress the secretion of HBsAg (in vitro, as well as in vivo in animal models, pre-clinical models, and clinical trials), and this review will focus on an overview of the different agents, and different strategies being pursued to develop methods of inhibiting the secretion of HBsAg, with a view to the cure of HBV. PMID: 28056752 [PubMed - as supplied by publisher] (Source: Infectious Disorders Drug Targets)
Source: Infectious Disorders Drug Targets - January 4, 2017 Category: Infectious Diseases Authors: Baugh SD Tags: Infect Disord Drug Targets Source Type: research
Tenofovir Alafenamide (Vemlidy) for Hepatitis B
Date: January 2, 2017 Issue #: 1511Summary: The FDA has approved tenofovir alafenamide (Vemlidy– Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product containing tenofovir alafenamide (TAF), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir, to become available; several combination products containing TAF are approved for treatment of HIV-1 infection. Tenofovir disoproxil fumarate (TDF;Viread– Gilead), another tenofovir prodrug, has been used for many years for treatment ...
Source: The Medical Letter - December 14, 2016 Category: Drugs & Pharmacology Authors: admin Tags: Adefovir Baraclude Entecavir Epivir-HBV hepatitis b Hepsera Heptovir lamivudine HBV Pegasys Peginterferon alfa-2a Sebivo telbivudine Tenofovir tenofovir alafenamide tyzeka Vemlidy Viread Source Type: research
Rabbit Syndrome developing during peginterferon alfa-2a use in Chronic Hepatitis C.
Authors: Soyer OM, Pehlivan A, Ormeci CA, Baran B, Sahin T PMID: 27595306 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 8, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Bevacizumab and interferon reduce venous recanalization following sclerotherapy
The treatment of venous malformations is difficult because these lesions frequently recur after resection or sclerotherapy. The purpose of this study was to determine whether recanalization of sclerosed venous lumens could be prevented with systemic angiogenic inhibition using bevacizumab or peginterferon alfa-2a. (Source: Journal of Pediatric Surgery)
Source: Journal of Pediatric Surgery - August 26, 2016 Category: Surgery Authors: Ann M. Kulungowski, Aladdin H. Hassanein, Carolyn C. Foster, Arin K. Greene, Steven J. Fishman Source Type: research
Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies
AbstractIntroductionWherever access to direct-acting antiviral agents is restricted, dual peginterferon/ribavirin (PegIFN/RBV) therapy remains an option for treatment of hepatitis C virus (HCV) genotype 4 (GT4) infection, which predominates in the Middle East and Sub-Saharan Africa. Our goal was to develop a baseline scoring system to identify GT4-infected patients with a low or high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV using data from two large cohort studies.MethodsAssociations between baseline characteristics and SVR were explored by generalized additive models and multip...
Source: Advances in Therapy - August 12, 2016 Category: Drugs & Pharmacology Source Type: research
CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study
Conclusions: PEG-INF-α2a plus ADV combination therapy is safe and superior to PEG-INF-α2amonotherapyfor decreasing serum HBV DNA and normalizing the ALT level but has no significant impact on the rate of HBeAg seroconversion and HBsAg loss. Adding ADV at week 12 may be an optimal combination strategy. (Source: Medicine)
Source: Medicine - August 1, 2016 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin
AIDS Research and Human Retroviruses Jul 2016, Vol. 32, No. 7: 660-667. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - June 27, 2016 Category: Infectious Diseases Authors: Tess PetersenYu-Jin LeeAnu OsinusiValerianna K. AmorosaCrystal WangMinhee KangRoy MatiningXiao ZhangDiana DouTriin UmblejaShyam KottililMarion G. Peters Source Type: research
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon and Cytokine Research)
Source: Journal of Interferon and Cytokine Research - June 21, 2016 Category: Molecular Biology Authors: Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan Source Type: research
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon)
Source: Journal of Interferon - June 21, 2016 Category: Research Authors: Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan Source Type: research
Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.
Authors: Li MH, Xie Y, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Hu LP, Hua WH, Song SJ, Zhang SF, Cheng J, Xu DZ Abstract AIM: To examine the association between interferon (IFN) therapy and loss of hepatitis B surface antigen (HBsAg) in inactive HBsAg carriers. METHODS: This was a retrospective cohort study in inactive HBsAg carriers, who were treatment-naive, with a serum HBsAg level
Source: World Journal of Hepatology - June 1, 2016 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Na ïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
Conclusion High SVR12 rates can be achieved with boceprevir plus peginterferon alfa-2a/ribavirin in treatment-na ïve HCV genotype 1 patients, including patients with well-compensated cirrhosis. Treatment is well tolerated when label restrictions are taken into account. Trial Registration Number ClinicalTrials.gov Identifier: NCT01591460. Funding F. Hoffmann-La Roche Ltd. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 1, 2016 Category: Infectious Diseases Source Type: research
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
Conclusion High SVR12 rates can be achieved with boceprevir plus peginterferon alfa-2a/ribavirin in treatment-naïve HCV genotype 1 patients, including patients with well-compensated cirrhosis. Treatment is well tolerated when label restrictions are taken into account. Trial Registration Number ClinicalTrials.gov Identifier: NCT01591460. Funding F. Hoffmann-La Roche Ltd. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - May 26, 2016 Category: Infectious Diseases Source Type: research
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun, 2016;15(3):333-349 Authors: Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Voss F, Gallivan JP, Böcher WO, Ferenci P, Ferenci P Abstract Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus ...
Source: Annals of Hepatology - April 9, 2016 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study
Abstract: Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n = 349; HBeAg negative, n = 90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse event...
Source: Medicine - April 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
, Noviello S Abstract AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin (pegIFN/RBV), in treatment-naive hepatitis C virus (HCV) genotype (GT) 1-infected patients. METHODS: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned (2:1) to daclatasvir vs telaprevir, stratified by IL28B rs12979860 host genotype (CC vs non-CC), cirrhosis status (compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype (GT1a vs GT1b). Patients were selected by study inclusion criteria from a total of 793 enrolled patients. Patients received ...
Source: World Journal of Gastroenterology : WJG - March 28, 2016 Category: Gastroenterology Authors: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin P Tags: World J Gastroenterol Source Type: research
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.
We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development. PMID: 26402250 [PubMed - in process] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - February 17, 2016 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Abstract Background and aim Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. Methods An international open-label trial was conducted in CHC patients with genotype (G)1/4 infection, compensated cirrhosis, HCV RNA ≥ 50,000 IU/mL and body mass index 18–35 kg/m2. Treatment-naive patients (Cohort 1) received a triple therapy regimen [danoprevir/r 100/100 mg twice daily (bid), ribavirin 1000/1200 mg/day and peginterferon alfa-2a 180 µg/week] f...
Source: Hepatology International - February 17, 2016 Category: Infectious Diseases Source Type: research
Interferons alfa-2a and -2b are biosynthetic forms of interferon alfa and consist of 165 amino acids. Interferons alfa-2a and -2b differ at amino acid position 23; alfa-2a has a lysine in that position, whereas -2b has an arginine at that position. Compared to other interferon alfa subtypes, interferons alfa-2a and -2b both have a deletion at position 44 in the amino acid sequence. [#] Peginterferon alfa-2a is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethlyene glycol (PEG) chain. The PEG moiety is linked at a single site via a stable amide bond to lysine. Peginterfero...
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research
Combination of Tenofovir Disoproxil Fumarate and Peginterferon alfa-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B
Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon alfa-2a (peginterferon), for a finite duration, in a randomized trial (Source: Gastroenterology)
Source: Gastroenterology - October 7, 2015 Category: Gastroenterology Authors: Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, Florin A. Caruntu, Won Young Tak, Magdy Elkashab, Wan-Long Chuang, Seng-Gee Lim, Fehmi Tabak, Rajiv Mehta, Joerg Petersen, Graham R. Foster, Lillian Lou, Eduardo B. Martins, Phillip Dinh, Lanjia Lin, Amoreena C Source Type: research
Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B
Quantitative serum HBsAg at week 48 and HBsAg level combined with HBeAg loss at week 72 of treatment can predict sustained virological response (SVR) to 96 weeks extended therapy with Peginterferon for chronic hepatitis B patients with poor response to the initial 48 weeks of Peginterferon treatment. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - October 3, 2015 Category: Virology Authors: Jie Chen, Dong-Hua Zhang, Cheng-Run Xu, Ming-Yu Zhu, Zhi-Tao Yang, Qi-Ming Gong, De-Min Yu, Xin-Xin Zhang Source Type: research
Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.
CONCLUSION: Lower pretreatment serum CXCL10 levels are associated with TD, and TD prevalence increases in female patients and patients who are positive for TPOAb at baseline. PMID: 26361424 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - September 7, 2015 Category: Gastroenterology Authors: Zhang RW, Shao CP, Huo N, Li MR, Xi HL, Yu M, Xu XY Tags: World J Gastroenterol Source Type: research
Simeprevir and sofosbuvir for treatment of hepatitis C infection.
CONCLUSION: Simeprevir and sofasbuvir have advantages in response rates and convenient dosage forms and frequency compared with other HCV treatments; however, they are more expensive than previous HCV therapies. PMID: 26294237 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - August 22, 2015 Category: Drugs & Pharmacology Authors: Chopp S, Vanderwall R, Hult A, Klepser M Tags: Am J Health Syst Pharm Source Type: research
Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis
Publication date: Available online 20 August 2015 Source:Clinics and Research in Hepatology and Gastroenterology Author(s): Zhengyan Wang, Ling Sun, Yuwan Wu, Qing Xia In the last decade, PEG-IFNa-2a has been widely used in the treatment of chronic hepatitis B (CHB). The current standard duration is 48 weeks; however, several studies based on small sample sizes have indicated that treatment extended beyond 48 weeks improved clinical outcomes than standard 48 weeks of therapy. Therefore, we performed a meta-analysis to compare the efficacy and safety of extended duration versus standard duration treatment with PEG-IFN...
Source: Clinics and Research in Hepatology and Gastroenterology - August 21, 2015 Category: Gastroenterology Source Type: research
Perspectives on dual hepatitis B and C infection in Taiwan
Publication date: Available online 15 July 2015 Source:Journal of the Formosan Medical Association Author(s): Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Tai-Chung Tseng, Jia-Horng Kao Dual hepatitis C virus (HCV) and hepatitis B virus (HBV) infection is not rare in HBV or HCV endemic areas, and can be found in populations at risk of parenteral viral transmission. Clinical observatory studies suggest a higher risk of liver disease progression in patients with dual HCV/HBV infection than in HBV or HCV monoinfected patients. Recent trials confirmed that combination therapy of peginterferon alfa-2a or alfa-2b and riba...
Source: Journal of the Formosan Medical Association - July 17, 2015 Category: Journals (General) Source Type: research
Perspectives on dual hepatitis B and C infection in Taiwan.
Abstract Dual hepatitis C virus (HCV) and hepatitis B virus (HBV) infection is not rare in HBV or HCV endemic areas, and can be found in populations at risk of parenteral viral transmission. Clinical observatory studies suggest a higher risk of liver disease progression in patients with dual HCV/HBV infection than in HBV or HCV monoinfected patients. Recent trials confirmed that combination therapy of peginterferon alfa-2a or alfa-2b and ribavirin was effective and safe in dually infected patients with positive HCV RNA. Moreover, about 30% of the dually infected patients cleared hepatitis B surface antigen within ...
Source: J Formos Med Assoc - July 15, 2015 Category: Journals (General) Authors: Liu CJ, Chen PJ, Chen DS, Tseng TC, Kao JH Tags: J Formos Med Assoc Source Type: research
Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
CONCLUSIONS: In Italian patients, a virologic response by Week 2 or 4 was highly predictive of SVR24 across genotypes. These data demonstrate the importance of monitoring on-treatment response to help guide treatment decisions. FIB-4 score correlated well with SVR24 in G1 patients. PMID: 26158171 [PubMed - in process] (Source: Hepato-Gastroenterology)
Source: Hepato-Gastroenterology - July 12, 2015 Category: Gastroenterology Tags: Hepatogastroenterology Source Type: research
Liver transplantation in a patient with hepatitis B, C and D coinfection associated with hepatocellular carcinoma: a management strategy for a rare condition. Case report.
CONCLUSION: OLT, in association with antiviral therapy using entecavir, which was administered before and after transplantation, was effective for sustained clearance of the hepatitis B and D viruses. A recurrence of hepatitis C infection after transplantation responded successfully to standard treatment comprising peginterferon alfa-2A and ribavirin. PMID: 26176835 [PubMed - as supplied by publisher] (Source: Sao Paulo Medical Journal)
Source: Sao Paulo Medical Journal - July 3, 2015 Category: Journals (General) Authors: Dantas LC, Genzini T, Miranda MP, Santos RG, Siqueira NG, Weirich J, Lobato CM Tags: Sao Paulo Med J Source Type: research
Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study
Abstract: In Myanmar, hepatitis C virus (HCV) infection prevalence is 2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating patients infected with HCV in Myanmar. This was a retrospective analysis of data from a single clinic exclusively for gastrointestinal diseases in Yangon, Myanmar. We assessed treatment responses at the defined time points and stratified by genotypes of HCV. We also determined incidences of adverse events (A...
Source: Medicine - July 1, 2015 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
l;ppe D Abstract Background and Aims: The efficacy and safety of peginterferon alfa-2a (PEG-IFN) plus ribavirin (RBV) and either boceprevir (BOC) or telaprevir (TVR), and physician adherence to treatment algorithms were evaluated in patients included in an ongoing non-interventional study (PAN) enrolling adults with chronic hepatitis C virus (HCV) infection managed in German office-based practices. Methods: The analysis included HCV genotype 1-infected, treatment-naïve and treatment-experienced patients treated with BOC or TVR. Demographic, treatment history, virological response, safety, and patient manageme...
Source: Zeitschrift fur Gastroenterologie - July 1, 2015 Category: Gastroenterology Authors: Mauss S, Böker K, Buggisch P, Christensen S, Hofmann WP, Schott E, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D Tags: Z Gastroenterol Source Type: research